Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?

Stephen J. Nicholls, Srinivasa Kalidindi, Steven E. Nissen

Research output: Contribution to journalArticlepeer-review


Clinical trials have unequivocally demonstrated that lowering levels of low-density lipoprotein cholesterol with statins prevents cardiovascular events. As a result, statins have become an integral component of therapeutic strategies to reduce cardiovascular risk. A number of important issues remain to be defined with regard to the optimal use of statin therapy in clinical practice. In particular, the ideal does, when to initiate therapy in relation to an acute ischemic event, and the duration of treatment remain uncertain. Results from a number of recently reported trials that investigate the impact of statin therapy on atherosclerotic plaque and clinical events provide further clarification with regard to these issues.

Original languageEnglish
Pages (from-to)290-295
Number of pages6
JournalCurrent Cardiovascular Risk Reports
Issue number4
Publication statusPublished or Issued - 1 Dec 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this